# Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

> **NCT00939588** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 88 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Aliskiren/ Valsartan
- **DRUG:** Telmisartan/ Ramipril

## Key facts

- **NCT ID:** NCT00939588
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939588, "Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00939588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*